Devyser Diagnostics AB (publ) Q2 2025 Earnings | 07/23/2025

About this video

Devyser Diagnostics AB (publ) reported strong financial results for the second quarter of 2025, delivering a significant swing to profitability and record sales. Net sales rose by 26.7% year-over-year to SEK67.4 million, up from SEK53.2 million in the same period last year, driven by increased direct and distributor sales and enhanced organizational efficiency. The company’s gross profit surged to SEK56.8 million, translating to an 84.3% gross margin, a notable improvement from 77.8% in Q2 2024. Profitability also strengthened across all metrics. EBITDA for the quarter reached SEK12.2 million, a marked turnaround from a negative SEK15.8 million a year earlier, resulting in an 18.1% EBITDA margin. Operating profit (EBIT) improved to SEK5.5 million from a loss of SEK22.7 million in the prior-year quarter, yielding an 8.2% operating margin. Net profit after tax was SEK1.3 million, compared to a loss of SEK22.9 million in Q2 2024. Basic and diluted earnings per share swung to SEK0.08 from a loss of SEK1.41 per share last year. Cash flow from operating activities was positive at SEK2.3 million, a significant improvement over the negative SEK15.5 million reported in the previous year’s second quarter. Cost-saving initiatives initiated at the start of 2025 have effectively lowered the company’s cost base while sustaining growth momentum, and the main one-off costs related to the program were absorbed earlier in the year. As a result, management anticipates these savings will have a more pronounced, positive impact on cash flow from autumn 2025 onward. In strategic developments, Devyser announced the appointment of Jan Wahlström as CEO, effective August 2025, aligning leadership with its ambitions in health care and life sciences. The company also celebrated winning a major SEK61.8 million tender in Italy and pushed forward with its U.S. commercial rollout, anticipating a MolDx program reimbursement decision that could expand clinical use later in the year. Management remains confident in the company’s ability to continue balancing investments in innovation with prudent cash management and expects Devyser’s improved financial position to enable sustained profitable growth as it enters the second half of the year. #DevyserDiagnostics #DVYSR #Q22025 #Earnings #FinancialResults #Profitability #SalesGrowth #EBITDA #OperatingProfit #NetProfit #GrossMargin #CostSavings #Diagnostics #Healthcare #LifeSciences #Innovation #MarketUpdate #InsideTicker #ShareholderReturns #CashFlow #StrategicGrowth #MolDx #ItalyTender #USExpansion